
|Articles|July 26, 2002
Flexible light-based system gets FDA nod
TheraLight received clearance from the U.S. Food and Drug Administrationto market its UV120-2 UVA/UUVB Phototherapy System for the treatment ofpsoriasis, vitiligo, atopic dermatitis and seborrheic dermatitis.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria
2
KT-621 Produces 98% STAT6 Degradation in AD Patients
3
Celldex Advances Barzolvolimab into Phase 3 for Cold Urticaria and Symptomatic Dermographism
4
A Patient–Physician Lens on the Real Burden of CHE
5



















